It has been demonstrated that epidermal growth factor receptor (EGFR) signal pathway had an important role in the oncogenesis and development of non-small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) that target at the kinase domain of EGFR are recently developed target therapy reagents for treatment of NSCLC patients. Previous studies revealed that different patient groups response differently to EGFR-TKI, which is based on the EGFR gene status. The aim of this research was to define the clinicopathologic features associated with the gene amplification and mutation status of the EGFR gene in NSCLC patients and determine the most likely population to benefit from TKI treatment.